Evaxion Biotech A/S ADR (NASDAQ:EVAX) Adds 12.14% In One Week: What’s Boosting Its Stock?

In last trading session, Evaxion Biotech A/S ADR (NASDAQ:EVAX) saw 55549.0 shares changing hands with its beta currently measuring -0.38. Company’s recent per share price level of $1.57 trading at -$0.04 or -2.48% at ring of the bell on the day assigns it a market valuation of $8.49M. That closing price of EVAX’s stock is at a discount of -766.88% from its 52-week high price of $13.61 and is indicating a premium of 18.47% from its 52-week low price of $1.28. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 64630.0 shares which gives us an average trading volume of 53.23K if we extend that period to 3-months.

For Evaxion Biotech A/S ADR (EVAX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 1 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 1 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.

Evaxion Biotech A/S ADR (NASDAQ:EVAX) trade information

Upright in the red during last session for losing -2.48%, in the last five days EVAX remained trading in the green while hitting it’s week-highest on Wednesday, 11/27/24 when the stock touched $1.57 price level, adding 14.21% to its value on the day. Evaxion Biotech A/S ADR’s shares saw a change of -77.10% in year-to-date performance and have moved 12.14% in past 5-day. Evaxion Biotech A/S ADR (NASDAQ:EVAX) showed a performance of -46.05% in past 30-days. Number of shares sold short was 36019.0 shares which calculate 1.27 days to cover the short interests.

Evaxion Biotech A/S ADR (EVAX) estimates and forecasts

Statistics highlight that Evaxion Biotech A/S ADR is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -56.38% of value to its shares in past 6 months, showing an annual growth rate of 81.48% while that of industry is 17.60. Apart from that, the company came raising its revenue forecast for fiscal year 2024.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -18.88% during past 5 years.